Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Biopsy confirmed cervical intraepithelial neoplasia (CIN) 2/3 or 3
• •* Planning loop excision or cone biopsy
• •* Diagnosis within 2 months prior to study entry
• •* Standard histological grading according to Richart
• •Visible lesion by colposcopy
• •* No unsatisfactory colposcopy or lesions extending into the endocervical canal that cannot be visualized entirely by colposcopy
• •No suspicion of invasive cervical cancer by cytology, histology or colposcopy
• •No cytologic evidence of glandular atypia or dysplasia
• •PATIENT CHARACTERISTICS:
• •Creatinine normal
• •Screening laboratory values within normal range (e.g., complete blood count, liver function tests, renal panel, and electrolytes)
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •Able to read and speak English or Spanish
• •No known hypersensitivity to bisphosphonates
• •Not immunocompromised
• •No known HIV positivity
• •No aspirin-sensitive asthma due to association of bisphosphonates with bronchoconstriction
• •No unexplained abnormal vaginal bleeding
• •PRIOR CONCURRENT THERAPY:
• •No concurrent loop diuretics, aminoglycosides, other nephrotoxic drugs, immunosuppressive drugs, or other investigational agents